In addition, the authors constructed two types of antibody-cell couplings (ACC) using a natural killer cell line (NK-92MI) and primary CD8+ T cells, and the modified cells exhibited specific tumor targeting and resistance to inhibitory signals generated by tumor cells, respectively. The gene discussed is CD8A; the disease is neoplasm.